Cash Runway Guidance: MacroGenics (MGNX) anticipates that its cash, cash equivalents and marketable securities balance of $146.4 million as of September 30, 2025, in addition to subsequent receipt of $75.0 million in partnering payments from Sanofi and Gilead, plus projected and anticipated future payments from partners and anticipated savings from the Company’s ongoing cost-reduction initiatives, is expected to support its cash runway into late 2027.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX:
- MGNX Earnings this Week: How Will it Perform?
- MacroGenics Advances in Cancer Treatment with MGC028 Clinical Trial
- MacroGenics’ Lorigerlimab Study: A Potential Game-Changer in Cancer Treatment?
- MacroGenics’ MGC026 Study: A New Hope for Advanced Cancer Treatment
- MacroGenics’ MGD024 Study: A New Hope for Blood Cancer Treatment?